This study aimed to assess the impact of testosterone undecylate on renal and hepatic functions by examining serum markers in obese and non-obese rats. The methodology involved treating these animals with testosterone undecylate or a control solution over a period of 28 days and analyzing serum samples for markers such as urea, creatinine, and liver enzymes. The results demonstrated no significant differences in creatinine, AST, ALT, GGT, ALP, and CK levels between the treated and control groups, suggesting that testosterone undecylate does not adversely affect renal or hepatic functions in the conditions tested. The study concludes that testosterone undecylate, within the administered doses, appears safe, presenting a favorable safety profile and good tolerability, making it a viable option for hormonal therapy in clinical and scientific settings.
No takes yet. Share an insight, caveat, or question.
Soares et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: